中医药治疗高血压早期肾损害的用药规律

Abstract
Figure/Table
References (29)
Related Citation (15)

Download: PDF (1319 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To study the medication rule of traditional Chinese medicine in the treatment of hypertensive early renal damage. Methods A database was established by collecting hypertensive early renal damage related journal articles recorded on CNKI, VIP and Wanfang database from inception to December 2021, and the frequency, nature and flavour and channel tropism, association rules, complex network visualization, system cluster analysis were conducted for the Chinese medicines that met the standards. Results Among the 69 Chinese herbal compounds that met the standard. It involved 140 Chinese medicines. Astragali Radix, Salviae Miltiorrhizae Radix Et Rhizoma, Cornifructus, Poria, Dioscoreae Rhizoma were the most used, the four nature of drugs were mainly flat, the five tastes were mostly sweet, bitter and spicy, and the channel tropism were mainly liver, spleen and kidney channels. In the results of association rules, there were seven binomial associations and seven three-term associations. The systematic clustering results were classified into four categories. Conclusion Traditional Chinese medicine in the treatment of hypertensive early renal damage mainly focuses on tonifying and replenishing liver and kidney, invigorating qi and strengthening spleen, calming the liver to stop the wind, draining turbidity and removing blood stasis, and treating both manifestation and root cause of disease.

Key words： Traditional Chinese medicine Data mining Hypertensive early renal damage Medication rule

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Kaili1 ZHANG Danhua1 XU Peicong1 WANG Baolin1 DENG Wei2

Cite this article:

CHEN Kaili1 ZHANG Danhua1 XU Peicong1 WANG Baolin1 DENG Wei2. Medication rule of traditional Chinese medicine in the treatment of hypertensive early renal damage[J]. 中国医药导报, 2022, 19(22): 118-122.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I22/118

[1] 陈晓平，崔兆强，林金秀，等.《2020国际高血压学会全球高血压实践指南》解读[J].中国医学前沿杂志（电子版），2020，12（5）：54-60.
[2] 中国高血压防治指南修订委员会.中国高血压防治指南2018年修订版[J].心脑血管病防治，2019，19（1）：1-44.
[3] 陈耀德，修建成.高血压肾病发病机制及早期筛查手段的研究进展[J].岭南急诊医学杂志，2021，26（3）：328-330.
[4] 王淑平，刘树军，李起奉，等.高血压所致肾损害患者临床及病理分析[J].中国实验诊断学，2021，25（11）：1683-1685.
[5] Zhang C，Fang X，Zhang H，et al. Genetic susceptibility of hypertension-induced kidney disease [J]. Physiol Rep，2021，9（1）：14688.
[6] Shimosawa T. Hypertension and its related organ damage-pathophysiology and new diagnostic strategy [J]. Rinsho Byori，2013，61（3）：263-270.
[7] 龙霖梓，褚剑锋，沈阿灵，等.中医药通过抗氧化途径防治高血压肾损害的研究进展[J].中西医结合心脑血管病杂志，2021，19（5）：765-769.
[8] 张薇，马开，周红艳，等.真武汤调控AVP/AQP2通路改善自发性高血压大鼠肾损伤研究[J].中药药理与临床，2021，37（5）：17-21.
[9] 中华医学会.临床诊疗指南·肾脏病学分册[M].北京：人民卫生出版社，2011：101.
[10] 宋立人.中华本草[M].上海：上海科学技术出版社，1999.
[11] 钟赣生.中药学[M].北京：中国中医药出版社，2019.
[12] 国家药典委员会.中华人民共和国药典[M].一部.北京：中国医药科技出版社，2020.
[13] 刘瑶，李伟.基于miRNA测序技术探讨黄芪-丹参药对干预自发性高血压大鼠肾损害的机制研究[J].中草药，2021，52（18）：5599-5607.
[14] Hou G，Jiang Y，Zheng Y，et al. Mechanism of Radix Astragali and Radix Salviae Miltiorrhizae ameliorates hypertensive renal damage [J]. Biomed Res Int，2021， 2021：5598351.
[15] 王悦，田双双，刘晓谦，等.茯苓多糖的提取、结构及药理作用研究进展[J].世界中医药，2021，16（17）：2548-2555.
[16] 娄文凤，张宁，布天杰.中药山茱萸治疗糖尿病肾脏疾病的作用机制探讨[J].临床肾脏病杂志，2021，21（10）：819-825.
[17] Zhou S，Huang G，Chen G. Extraction，structural analysis，derivatization and antioxidant activity of polysaccharide from Chinese yam [J]. Food Chem，2021，361：130089.
[18] 范晓阳，侯彦婕，贾世艳，等.山药化学成分及皂苷类成分药理作用的研究进展[J].中医药信息，2021，38（9）：79-84.
[19] 严斐霞，谢永艳，陈畅，等.熟地黄炮制过程中的化学成分变化和药理作用研究进展[J].时珍国医国药，2021， 32（10）：2493-2495.
[20] 胡建燃，李平，王俊瑶.熟地黄多糖的提取及其体外抗氧化活性研究[J].中华中医药学刊，2021，39（12）：37-41.
[21] 陈潇颖，殷立平.中药基于Nrf2信号通路干预糖尿病肾病的研究进展[J].广州中医药大学学报，2021，38（9）：2036-2041.
[22] 蒋鹤飞，杨小四.丹皮酚抗炎作用实验研究进展[J].中国医药科学，2022，12（5）：53-56，137.
[23] Zhang ZM，Yang L，Wan Y，et al. The synergic renoprotective effect of Rehmanniae Radix Preparata and Corni Fructus on adenine-induced chronic kidney disease rats based on integrated plasma metabolomics and network pharmacology approach [J]. Life Sci，2021，278：119545.
[24] 张维君，韩东卫，李冀.泽泻的化学成分及药理作用研究进展[J].中医药学报，2021，49（12）：98-102.
[25] 董月桂，易健，刘柏炎.六味地黄丸联合奥美沙坦酯片治疗高血压病早期肾损伤34例[J].湖南中医杂志，2021， 37（8）：45-47.
[26] 郝瑞，邵蒙苏，张博荀.石决明的临床应用及其用量探究[J].吉林中医药，2021，41（4）：536-539.
[27] 张蓓蓓，方媛，王晗.浅述高血压肾损害的病机及中医药治疗的临床研究进展[J].中医药临床杂志，2021，33（5）：1003-1007.
[28] 刘淑芳，柳向颖，张琳.中医药防治高血压肾损害的研究进展[J].中国医药导报，2020，17（35）：49-52.
[29] 蒋芙苓，何民，吴静，等.天麻钩藤饮联合耳尖放血辅助治疗阴虚阳亢型高血压急症、亚急症临床研究[J].新中医，2021，53（18）：67-71.